Navigation Links
XTL Biopharmaceuticals Announces Receipt of NASDAQ Notice of Delisting
Date:1/28/2009

VALLEY COTTAGE, N.Y., Jan. 28 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, TASE: XTL) today announced that on January 27, 2009 it received a Staff Determination Letter (the "Letter") from The Nasdaq Stock Market ("Nasdaq") notifying the Company that the staff of Nasdaq's Listing Qualifications Department determined, using its discretionary authority under Nasdaq Marketplace Rule 4300, that the Company's American Depository Shares ("ADRs") would be delisted from Nasdaq. The Letter further stated that Nasdaq would suspend trading in the Company's ADRs at the opening of trading on February 5, 2009 and then file a Form 25-NSE with the Securities and Exchange Commission ("SEC") to deregister the Company's ADRs, unless the Company appeals Nasdaq's delisting determination. Nasdaq's determination to delist the ADRs was based on Nasdaq's belief that the Company was a public shell and that the Company does not meet the stockholder's equity requirement or any of its alternatives.

The Letter also indicated that, in accordance with the procedures set out in Marketplace Rule 4800 Series, the Company would have seven (7) calendar days, or until February 3, 2009, to appeal the delisting from Nasdaq to a Listing Qualifications Panel. At this time, the Company does plan to appeal the delisting from Nasdaq. There can be no assurance that the appeal will be successful.


'/>"/>
SOURCE XTL Biopharmaceuticals Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
2. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
3. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
4. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
5. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
6. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
7. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
8. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
9. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
10. Morria Biopharmaceuticals Plc Appoints Dr. Johnson Lau and Dr. David Sidransky to Board of Directors
11. XTL Biopharmaceuticals Ltd. AGM / EGM Postponed Until October 2, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Calif. , Sept. 2, 2014  Xencor, ... biopharmaceutical company developing engineered monoclonal antibodies for the ... and cancer, today announced the appointment of ... development and the appointment of Lloyd Rowland ... general counsel. "Debra,s expertise in ...
(Date:9/2/2014)... Sept. 2, 2014  Spherix Incorporated (SPEX) -- an intellectual property ... intellectual property, today announced that the United States Patent ... Company in the month of August that are part ... The issued patents are: , ... August 19, 2014; and , U.S.RE45,095 issued August ...
(Date:9/1/2014)... The Collaborative R&D Terms and ... comprehensive understanding and unprecedented access to the collaborative ... worlds leading life science companies. , The report ... and why companies enter collaborative R&D deals. , ... deals terms provides critical insight into the negotiation ...
(Date:8/30/2014)... Dallas, TX (PRWEB) August 31, 2014 ... Industry is a professional and in-depth study on ... industry in Global and China. , The report ... definitions, applications and industry chain structure. Global market ... with a focus on history, developments, trends and ...
Breaking Biology Technology:Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 3United States Patent & Trademark Office Issues Three New Standard Essential Patents to Spherix 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 3Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 4Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 2Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 3
... Kauten is taking direct aim at three unfavorable metrics, and ... , ,Kauten, CEO of QBI Life Sciences , recently ... Polymeric Micelles, a core product. The screening, which employed UGT1A1, ... is used to determine whether a drug will become active ...
... that is developing technologies for the $6 billion worldwide wound ... , ,The company, which was honored during an awards ceremony ... of 27 finalists that presented business plans to a panel ... which drew 200 entries, it will collect prizes of at ...
... Telecommunications, Inc. has introduced the Enhanced Mail Guardian, ... for organizational networks. , ,Enhanced Mail Guardian's features include ... be customized to handle encrypted e-mails that are specific ... sort e-mails and attachments based on key words like ...
Cached Biology Technology:QBI's PreserveX product passes initial test 2QBI's PreserveX product passes initial test 3MatriLab wins Governor's Business Plan Contest 2MatriLab wins Governor's Business Plan Contest 3MatriLab wins Governor's Business Plan Contest 4
(Date:9/1/2014)... and decisions of the Nomenclature Section of the XVIII ... July 2011. This meeting is held every six years ... the rules for naming algae, fungi and plants get ... naming the organisms they study. This is the primary ... for algae, fungi, and plants, which was published in ...
(Date:8/31/2014)... A fast-sensitive "electronic-nose" for sniffing the highly infectious bacteria ... stomach cramps, has been developed by a team at ... the research team has demonstrated that it is possible ... which would lead to rapid diagnosis of the ... could be possible to identify different strains of the ...
(Date:8/31/2014)... of satellite data from the last 19 years reveals that ... the coast of Antarctica to rise by 2cm more than ... of Southampton detected the rapid rise in sea-level by studying ... million square kilometres. , The melting of the ... has contributed an excess of around 350 gigatonnes of freshwater ...
Breaking Biology News(10 mins):Week-long meeting on naming algae, fungi, and plants recorded for posterity 2Scientists develop 'electronic nose' for rapid detection of C. diff infection 2
... research shows an increased risk of ischemic stroke in postmenopausal ... found in baked goods, fried foods, and packaged products. Study ... journal published by Wiley-Blackwell on behalf of the American Neurological ... the stroke risk caused by a diet high in trans ...
... NY, February 29, 2012Although industrial parks are often ... which they reside, they can also consume environmental ... affect human health and quality of life. A ... ( http://www.liebertpub.com/ees ), a peer-reviewed journal from ...
... supercomputer has completed the first phase of an ... powerful scientific computing systems in the world. ... this month. The testing suite included leading scientific ... fusion, and combustion. Jaguar, manufactured by Cray ...
Cached Biology News:Postmenopausal women at greater risk of stroke from high trans fat intake 2Can industrial parks be more environmentally friendly? 2ORNL completes first phase of Titan supercomputer transition 2
... 1, active MW: 34.2kDa Formulation: 10mM ... Brij-35, 1mM dithiothreitiol with 50% glycerol ... to the Certificate of Analysis for ... salt precipitation followed by gel filtration ...
MitoScreen (JC-1) Kit , 100 tests Consult technical datasheet for details....
Thermal Printer Paper for Monolight(tm) Luminometer 1 each...
Conjugate Quality Control Evaluation Specificity: Conjugate Quality Control Evaluation ...
Biology Products: